🇳🇵 Nepal Demands Grants to Rebuild

Nepal says rebuilding after its glacier flood will cost about 10% of GDP and is asking international donors for grants.

Speaking at the UN General Assembly on September 24, Prime Minister Balendra Shah said Nepal should not have to take on more debt to recover from the disaster. The flood struck four weeks ago; the new development is the government's reconstruction estimate and financing demand. Reuters reports at least 1,450 deaths and more than 6,000 people still missing. [Reuters reporting](https://kelo.com/2026/09/24/nepal-seeks-grants-not-loans-for-flood-recovery-after-deadly-glacier-disaster/)

Shah also called for Nepal, India and China to share satellite data, monitor glacial lakes and coordinate warnings and disaster responses. The World Bank earlier this week made up to $170 million in emergency financing available. That commitment does not establish that Nepal's request for adequate grant funding has been met. [Reuters reporting](https://kelo.com/2026/09/24/nepal-seeks-grants-not-loans-for-flood-recovery-after-deadly-glacier-disaster/)

Why it matters: Our assessment: the financing terms will shape the damage long after floodwaters recede. Rebuilding through additional borrowing could squeeze spending on schools, health care and protection against the next disaster.

🤖 Washington Seeks First Look at New AI Models

The White House reportedly asked OpenAI and Anthropic to withhold new models from British testers until a US review.

Reuters reported on September 24 that Politico had learned of the request from a person familiar with the matter and a senior administration official. The stated aim is to establish that US systems are secure before sharing them with partners. The White House and both companies had not immediately responded to Reuters; the request remains reported policy, without a publicly confirmed scope or timetable. [Reuters reporting](https://currently.att.yahoo.com/att/white-house-asks-openai-anthropic-174618082.html)

Why it matters: Our assessment: controlling who tests a model, and when, can affect whether outside evaluators identify dangerous capabilities before deployment. The pressure point is whether a US review improves security while preserving timely scrutiny by allied testers.

🏦 Norway Raises Rates Again

Norges Bank raised its policy rate by a quarter point to 4.5%, effective September 25, and left further increases on the table.

Governor Ida Wolden Bache said inflation had remained above target for several years and that borrowing costs would likely need to stay elevated. The September 24 announcement explicitly retained the option of another increase if needed to bring inflation down. [Norges Bank statement](https://www.norges-bank.no/en/news-events/news/Speeches/2026/2026-09-24-pc/)

The bank's revised forecast keeps rates elevated longer than its June projection and puts inflation's return to 2% in 2029. It also expects the economy to cool further and registered unemployment to rise modestly. Those are forecasts, not settled outcomes. [Norges Bank decision](https://www.norges-bank.no/en/topics/monetary-policy/Monetary-policy-meetings/2026/september-2026/)

Why it matters: Our assessment: households and businesses planning around imminent borrowing relief face a longer squeeze. The bank is accepting weaker activity to prevent persistent inflation from becoming harder to dislodge.

👁️ Eye Drug Clears Trial Goal With Safety Questions

Merck's experimental diabetes-related eye treatment met its main trial goal, but several adverse outcomes were more frequent than with the comparator.

Merck announced September 24 that both tested doses of remigromig met the BRUNELLO trial's non-inferiority goal against ranibizumab for changes in visual acuity at 52 weeks. The study enrolled adults with diabetic macular edema. Meeting that threshold does not establish that the experimental drug improves vision more than the existing treatment. [Merck announcement](https://uk.finance.yahoo.com/news/merck-remigromig-tri-specific-agonist-104500588.html)

Merck also reported higher rates of proliferative diabetic retinopathy, bleeding into the eye and treatment discontinuation because of adverse events in the remigromig groups. Further analysis is underway, with first-year results scheduled for presentation on October 10. The treatment remains investigational. [Merck announcement](https://uk.finance.yahoo.com/news/merck-remigromig-tri-specific-agonist-104500588.html)

Why it matters: Our assessment: a different treatment mechanism could expand options, but the safety findings are central to judging its value. The full results need to show how any benefits compare with the additional adverse outcomes.

🚢 Fresh Missiles Threaten Saudi Export Recovery

Saudi Arabia reported intercepting six Houthi ballistic missiles aimed at Taif and the Yanbu area as its oil export recovery remained incomplete.

The September 24 interceptions put fresh pressure on the Red Sea export corridor covered earlier this week. The Houthis claimed attacks on Riyadh and Aramco facilities; those claims should not be treated as confirmation of successful strikes or damage. [Reuters reporting](https://www.al-monitor.com/originals/2026/09/saudi-arabia-says-it-intercepted-houthi-missiles-group-claims-strikes-riyadh)

Reuters reported that Saudi Arabia was increasing pumping through its repaired East-West Pipeline, but tanker loadings had yet to resume, according to industry sources, satellite imagery and shipping data. Oil settled roughly 3% higher on September 24 as the attack renewed supply concerns. Restarting the pipeline has not yet established a fully functioning export route. [Reuters reporting](https://www.marketscreener.com/news/oil-prices-jump-4-as-houthis-fire-missiles-at-saudi-arabia-ce785aded08df725)

Why it matters: Our assessment: the meaningful recovery measure is cargo leaving port. Until pumping, loading and safe passage work together, fuel buyers remain exposed to disruptions despite completed repairs.

🧠 The Bottom Line

Financing and execution carry the consequences today: Nepal needs reconstruction money on workable terms, Norway is extending the borrowing squeeze, and Saudi export recovery still depends on ships loading and departing.

The same discipline applies to AI and medicine: access to testing and complete safety evidence matter. A government review request or a successful trial headline leaves critical questions unresolved.